Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
New England Journal of Medicine, 2021 Heterologous Vaccination with ChAdOx1 nCoV-19 and mRNA-1273 Health care workers who had received a dose of ChAdOx1 nCoV-19 were offered a choice of receiving either ChAdOx1 nCoV-19 or mRNA-1273 9 t...
Johan Normark +12 more
openaire +4 more sources
AZD1222 (ChAdOx1 nCoV-19) Vaccine: Hurdles and Visions
Journal of Pure and Applied Microbiology, 2023 ChAdOx1 nCoV-19 (AZD1222) is a replication-deficient chimpanzee adenovirus vectored vaccine developed by Oxford and AstraZeneca for a disease we all know as Coronavirus, or COVID-19. Ongoing clinical studies reveal that the ChAdOx1 nCoV-19 vaccine has a tolerable safety profile and is effective against symptomatic COVID-19.
Md. Altamash Ahmad +8 more
openaire +4 more sources
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults [PDF]
Human Vaccines & ImmunotherapeuticsAZD1222 (ChAdOx1 nCoV-19) is a replication-deficient adenoviral vectored coronavirus disease-19 (COVID-19) vaccine that is manufactured as SII-ChAdOx1 nCoV-19 by the Serum Institute of India Pvt Ltd following technology transfer from Oxford University ...
Prasad S. Kulkarni +31 more
doaj +4 more sources
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study [PDF]
The Lancet Regional Health. Europe, 2021 Summary: Background: The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. Methods: From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we ...
Peter Nordström +2 more
doaj +2 more sources
Vaccines, 2022 Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) were found to have a decreased immune response following mRNA COVID-19 immunization.
Wisit Prasithsirikul +7 more
doaj +2 more sources
Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies [PDF]
Clinical and Experimental Vaccine Research, 2023 The present study aimed to study the immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies.This prospective cohort study of hematology patients aimed to evaluate their antibody levels against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 spike protein and seroconversion rates ...
Chayapa Thookhamme +6 more
openaire +3 more sources
Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination [PDF]
iScience, 2022 Summary: Heterologous SARS-CoV-2 vaccine approaches with a second mRNA-based vaccine have been favored in the recommendations of many countries over homologous vector-based ChAdOx1 nCoV-19 vaccination after reports of thromboembolic events and lower ...
Markus Bauswein +8 more
doaj +2 more sources
A case report of ChAdOx1 nCoV-19 vaccine–associated encephalitis [PDF]
BMC Neurology, 2021 Abstract Background Vaccination against COVID-19 continues apace, but side-effects, both common and severe, continue to be reported. We report here the first published case of COVID-19 vaccine-related encephalitis.
Takata, J +5 more
openaire +6 more sources
ChAdOx1 nCoV-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome among Adults: A Systematic Review [PDF]
Advanced Pharmaceutical Bulletin, 2023 Several vaccine-induced thrombotic thrombocytopenia syndrome (VITTS) cases have been reported after the ChAdOx1 nCov-19 vaccination. The current study systematically reviewed the reported post-ChAdOx1 nCoV-19 vaccination thrombotic thrombocytopenia cases.
Homa Faghihi +3 more
doaj +2 more sources
Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations [PDF]
Annals of Laboratory Medicine, 2022 While numerous studies have evaluated humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, data on the cellular responses to these vaccines remain sparse. We evaluated T cell responses to ChAdOx1-nCoV-19 and BNT162b2 vaccinations using an interferon gamma (IFN-γ) release assay (IGRA). ChAdOx1-nCoV-19- and BNT162b2-
Tae Hwan Lee +7 more
openaire +3 more sources